Monica Bhatia, MD

Expertise in: 
Cancer Care
Board Certifications: 
Pediatric Hematology-Oncology, Pediatrics
Accepting New Patients
Treats Children
Profile Headshot

Overview

Areas of Expertise / Conditions Treated

Cancer Care, Acute Myeloid Leukemia, Bone Marrow Disorders, Bone Marrow Stem Cell Transplants, Chemotherapy, Hemoglobinopathy, Immunodeficiency Disorder, Sickle Cell Anemia, Pediatric Bone Marrow

Academic Appointments

  • Associate Professor of Pediatrics at CUMC

Administrative Titles

  • Director, Pediatric Stem Cell Transplant Program

Monica Bhatia, MD specializes in the care of children with noncancerous blood disorders who may benefit from bone marrow transplantation, especially sickle cell anemia. She and her colleagues are working to reduce the toxicity (side effects) and complications of this treatment without compromising its effectiveness, and to make it available to more patients.

The field of pediatric hematology brings with it many intellectual challenges, and bone marrow transplantation in particular is especially dynamic. Dr. Bhatia has the opportunity to provide care for the sickest children, potentially curing their disease. She builds strong relationships with her patients and their families that last for years. It is inspiring for her to see young patients grow up to lead healthy, productive lives.

NewYork-Presbyterian/Morgan Stanley Children's Hospital has a robust program for bone marrow transplantation for sickle cell anemia - the only cure for this disease. Dr. Bhatia and her team have witnessed remarkable results among children who are cured with bone marrow transplantation and spared from the potentially life-threatening complications of sickle cell disease.

Yet despite the advances made, only 15 percent of patients with sickle cell disease have a matched sibling bone marrow donor. Therefore, Dr. Bhatia and her team conduct research to evaluate a procedure called "CD34-selected stem cell transplantation" to remove T-cells from donor bone marrow for patients without a matched sibling donor. This approach reduces the risk of graft-versus-host disease (GVHD), a potential complication of bone marrow transplantation in which T-cells from the donor attack the tissue of the recipient. This approach to harnessing stem cells could potentially make bone marrow transplantation a safer, effective option for many patients who are seeking a cure for sickle cell disease.

Dr. Bhatia and her colleagues are currently assessing reduced-intensity transplantation, which uses lower doses of chemotherapy to decrease the risk of side effects and long-term complications without lowering the effectiveness of treatment. She is also interested in looking for ways to further improve the quality of life of patients who have had a bone marrow transplant in addition to fertility preservation.

Hospital Affiliations

  • NewYork-Presbyterian/Morgan Stanley Children's Hospital
  • NewYork-Presbyterian/Columbia

Gender

  • Female

Schedule an Appointment

Phone Appointments

New and Existing Patients:

Location(s)

CUMC/NewYork-Presbyterian Morgan Stanley Children's Hospital
3959 Broadway
New York, NY 10032
Primary
CUMC/Herbert Irving Pavilion
161 Fort Washington Avenue
New York, NY 10032

Insurance Accepted

Aetna

  • EPO
  • HMO
  • Medicare Managed Care
  • NY Signature
  • NYP Employee Plan
  • POS
  • PPO
  • Signature Administrators
  • Student Health

Affinity

  • Essential Plan
  • Medicaid Managed Care

Amida Care

  • Special Needs Plan

Cigna

  • EPO
  • Great West
  • HMO
  • POS
  • PPO

Emblem/GHI

  • Medicare Managed Care
  • PPO

Emblem/HIP

  • ConnectiCare
  • EPO
  • Essential Plan
  • HMO
  • Medicaid Managed Care
  • Medicare Managed Care
  • POS
  • PPO
  • Select Care (Exchange)
  • Vytra

Empire Blue Cross Blue Shield

  • EPO
  • Medicare Managed Care
  • PPO

Empire Blue Cross Blue Shield HealthPlus

  • Child/Family Health Plus
  • Essential Plan
  • Medicaid Managed Care

Fidelis Care

  • Child/Family Health Plus
  • Medicaid Managed Care
  • Medicare Managed Care

Healthfirst

  • Child/Family Health Plus
  • Leaf (Exchange)
  • Medicaid Managed Care
  • Medicare Managed Care

Local 1199

  • Local 1199

MagnaCare

  • MagnaCare

Multiplan

  • Multiplan

MVP Health Care

  • Child/Family Health Plus
  • Essential Plan
  • HMO
  • Medicaid Managed Care

Oxford Health Plans

  • Freedom
  • Liberty

UnitedHealthcare

  • Columbia University Employee Plan
  • Compass (Exchange)
  • HMO
  • Medicaid (Community Plan)
  • Medicare Managed Care
  • POS
  • PPO

VNSNY CHOICE

  • Medicare Managed Care
  • SelectHealth
  • Special Needs Plan

WellCare

  • Medicaid Managed Care
  • Medicare Managed Care

*Please contact the provider’s office directly to verify that your particular insurance is accepted.

Credentials & Experience

Education & Training

  • St. George's University School of Medicine (Grenada)
  • Residency: Albany Medical Center Hospital, NY
  • Fellowship: Childrens National Medical Center

Board Certifications

  • Pediatric Hematology-Oncology
  • Pediatrics
NY Top Doctor

Research

Clinical Trials

NCT00408447 Allogeneic Stem Cell Transplant to Induce Mixed Donor Chimerism in Patients With Sickle Cell Disease and Thalassemia

NCT00920972 A Study of Hematopoietic Stem Cell Transplantation (HSCT) in Non-Malignant Disease Using a Reduced-Intensity Preparatory Regime

NCT02452034 A Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous (IV) and Powder for Oral Suspension Formulations of Posaconazole (POS) in Immunocompromised Pediatric Subjects With Neutropenia

NCT02766465 A Study to Compare Bone Marrow Transplantation to Standard Care in Adolescents and Young Adults With Severe Sickle Cell Disease (BMT CTN #1503)

NCT02851407 A Phase 3, Randomized, Adaptive Study Comparing the Efficacy and Safety of Defibrotide vs Best Supportive Care in the Prevention of Hepatic Veno-Occlusive Disease in Adult and Pediatric Patients Undergoing Hematopoietic Stem Cell Transplant

NCT02867800 Abatacept for Graft Versus Host Disease Prophylaxis After Hematopoietic Stem Cell Transplantation for Pediatric Sickle Cell Disease: a Sickle Transplant Alliance for Research Trial

Grants

A PHASE 1/2 STUDY OF THE SAFETY AND EFFICACY OF A SINGLE DOSE OF AUTOLOGOUS CRISPR-CAS9 MODIFIED CD34+ HUMAN HEMATOPOIETIC STEM AND PROGENITOR CELLS (HHSPCS) IN SUBJECTS WITH TRANSFUSION-DEPENDENT -THALASSEMIA (P&S Industry Clinical Trial)

Dec 20 2019 - Dec 19 2024

A PHASE 1/2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF A SINGLE DOSE OF AUTOLOGOUS CRISPR-CAS9 MODIFIED CD34+ HUMAN HEMATOPOIETIC STEM AND PROGENITOR CELLS (CTX001) IN SUBJECTS WITH SEVERE SICKLE CELL DISEASE (P&S Industry Clinical Trial)

May 15 2019 - May 15 2024

PROBIOTICS FOR PREVENTION OF ACUTE GRAFT-VS-HOST DISEASE IN CHILDREN WITH CANCER (Federal Gov)

Jan 1 2019 - Jul 31 2023

A PHASE 3, RANDOMIZED, ADAPTIVE STUDY COMPARING THE EFFICACY AND SAFETY OF DEFIBROTIDE VS BEST SUPPORTIVE CARE IN THE PREVENTION OF HEPATIC VENO-OCCLUSIVE DISEASE IN ADULT AND PEDIATRIC PATIENTS (P&S Industry Clinical Trial)

Apr 21 2017 - Apr 21 2022

PROBIOTICS FOR PREVENTION OF ACUTE GRAFT-VS-HOST DISEASE IN CHILDREN WITH CANCER (Federal Gov)

Sep 6 2016 - Jul 31 2021

MINIMIZING TOXICITY IN HLA-IDENTICAL SIBLING TRANSPLANTATION FOR CHILDREN WITH SICKLE CELL DISEASE (Private)

Apr 1 2019 - Aug 31 2020

MASTER PER CASE REIMBURSEMENT AGREEMENT FOR PARTICIPATION IN THE PEDIATRIC BLOOD MARROW TRANSPLANTATION CONSORTIUM (Federal Gov)

Sep 1 2008 - Aug 31 2018

NMDP BMT-CTN CLINICAL PROTOCOL #0601 (Federal Gov)

Jul 1 2013 - Jun 30 2018

PRIMARY IMMUNE DEFICIENCY TREATMENT CONSORTIUM (Federal Gov)

Sep 1 2016 - Aug 31 2017

APPLYING BIOMARKERS TO LONG-TERM EFFECTS IN CHILD (Private)

Jun 3 2014 - Sep 30 2016

HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR YOUNG ADULTS WITH SICKLE CELL DISEASE (Federal Gov)

Sep 1 2015 - Jul 31 2016

UNRELATED DONOR HEMATOPOIETIC CELL TRANSPLANTATION FOR CHILD REN WITH SEVERE SICKLE CELL DISEASE USING A REDUCED INTENSIT (Federal Gov)

Feb 1 2009 - Jun 1 2013